MeVis Medical Solutions AG

M&A Activity • Apr 10, 2008

News Details

Corporate | 10 April 2008 13:53

MeVis Medical Solutions complements product portfolio through strategic investment

MeVis Medical Solutions AG / Acquisition/Agreement

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

MeVis Medical Solutions complements product portfolio through strategic
investment:
Acquisition of Pulmonary Computed Tomography (CT) Business from Hologic R2

Bremen, April 10, 2008 - MeVis Medical Solutions AG announced today that it
has acquired the computed tomography (CT) software business of Hologic R2
Inc., a subsidiary of Nasdaq-listed Hologic Inc. The acquisition includes
R2 products, technology and intellectual property for
computer-aided-detection (CAD), advanced visualization and analysis of
multi-slice CT (MSCT) lung exams and establishes new partnerships with
leading medical imaging OEMs which are complementary to MeVis’ existing
customer base. The acquired business provides the foundation for a
significant expansion of the MeVis’ product portfolio of workflow-optimized
solutions for pulmonary imaging and oncology. The acquisition, which is in
the mid-seven figure range (EUR), further demonstrates MeVis’ strategy to
expand its technology basis and support further product development.

'We are extremely excited about the acquisition of these best-in-class
Hologic R2 products and technologies to compliment our solutions portfolio
for image-based medicine,' commented Thomas Tynes, board member of MeVis
Medical Solutions AG and President and CEO of MeVis’ U.S.-based subsidiary.
'We are sure to benefit from this investment and expect a significant
impact on our sales and earnings over the next several years, when we will
be able to exploit synergies from the introduction of new products based on
the combined Hologic R2 and MeVis know-how.'

The acquired product, ImageChecker CT, was the first CT Lung CAD system
approved by the U.S. Food and Drug Administration (FDA) for the detection
of actionable lung nodules during review of multi-slice CT chest exams. Its
CAD algorithms serve as the physician's 'second pair of eyes' by examining
a CT chest study and automatically marking areas that warrant further
examination - enabling increased diagnostic accuracy and physician
productivity. MeVis will transfer the current business to its new
Milwaukee, Wisconsin-area facility and distribute the associated existing
products under a new brand name as the MeVis Visia CT Lung System with the
following capabilities, features and benefits:

• Lung Nodule Detection using proprietary CAD technology, to automatically
and accurately highlight, analyze and measure potential actionable lung
nodules

• Temporal Comparison to match and measure candidate nodules on current and
prior exams and help determine therapy effectiveness

• Pulmonary Artery Analysis to automatically detect and examine pulmonary
artery abnormalities, such as pulmonary emboli

• Automated Reporting including seamless integration into Picture Archiving
and Communications Systems (PACS) for an enterprise-wide workflow

MeVis Visia CT Lung System is taking the technology for early detection of
lung cancer to the next level and ultimately supports physicians in saving
lives. According to the American Cancer Society (ACS), lung cancer accounts
for the most cancer-related deaths in both men and women accounting for
about 29 percent of all cancer deaths. Lung cancer is extremely difficult
to detect in its early stages, leading to a five-year survival rate as low
as 15 percent for all stages of lung cancer. If lung cancer is found and
treated while it is localized, however, this survival rate increases to 49
percent. Unfortunately, at present, only about 16 percent of lung cancers
are found in the early stages. MeVis is committed to improving the early
detection of cancer. Based on more than 10 years of technical and clinical
research and development through its German research and development
facility, MeVis has also established an international leadership position
in software technology for the evaluation of obstructive and diffuse lung
disease and invests in constant innovation.

'The existing FDA-approved, clinically validated products will allow us to
serve current customers while laying the foundation for future innovation
in the fight against lung disease,' explained Thomas Tynes. 'The
combination of the acquired Hologic R2 products along with our existing
technology, will provide the most comprehensive, clinically relevant
solutions for the detection, evaluation and treatment of pulmonary disease
and disorders.'

About MeVis Medical Solutions
MeVis Medical Solutions AG was founded in Bremen in 1997, and is one of the
world’s leading independent manufacturers of innovative, high-quality
software products for image-based medicine, in particular digital
radiology. The company develops and markets specialized, proprietary
software solutions to support the screening, diagnosis, intervention, and
surgery for specific clinical conditions, particularly in the areas of
oncology, neurology, and surgery. MeVis Medical Solutions primarily markets
its products through the world’s leading companies in the medical
technology market. The company has about 100 employees and is listed in the
Prime Standard of the Frankfurt Stock Exchange since November 2007.

MeVis Medical Solutions AG
Dr. Olaf Sieker, CFO
Tel: +49 421 22495-36
E-mail: olaf.sieker@mevis.de

Press and Investor Relations:
HOSCHKE & CONSORTEN Public Relations GmbH
Fabian Lorenz, Grit Pauli
Tel: +49 40 3690 50-56 / -31
E-mail: f.lorenz@hoschke.de; g.pauli@hoschke.de

10.04.2008 Financial News transmitted by DGAP

Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: office.mms@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE

End of News DGAP News-Service

---